STING1 and hepatocellular carcinoma: As an immune checkpoint molecule on immunosuppressive B-cells, TIM-1 holds promise for guiding the development of new combination therapies that enhance the efficacy of STING agonists, offering new hope for the immunotherapy of HCC.